Schisandra chinensis ethyl hydrate extract and uses thereof, and anti AIDS pharmaceutical combination

Abstract

The invention relates to an ethanol extract from schisandra chinensis, the application thereof and an anti-hiv drug combination, and discloses a therapeutic drug combination which comprises atazanavir that is compounded with the ethanol extract from the schisandra chinensis; wherein, the compounded proportion by weight of the atazanavir and the ethanol extract from the schisandra chinensis (by Schizandrin A) is 6:1 to 1:3. The ethanol extract adopts the atazanavir to combine with the the ethanol extract from the schisandra chinensis, and the plasma concentration of the atazanavir is effectively increased, thereby reducing the dosage of the atazanavir; experiments prove that the anti-hiv drug combination has less toxic and side effects, and can reduce the adverse reaction during the treatment process of aids.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a compound medicine for treating AIDS. Background technique [0002] AIDS, at present, people in almost all countries in the world are infected with this disease, and millions of people die from AIDS every year. In recent years, AIDS in my country has been on the rise year by year. At present, AIDS has been reported in 30 provinces, municipalities and autonomous regions. Since the first AIDS patient was discovered in the 1980s, a variety of drugs that inhibit the virus replication process have been developed, including nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, etc. . The currently recommended first-line treatment regimen for HIV-infected patients consists of protease inhibitors combined with two nucleoside reverse transcriptase inhibitors to produce high-potency antiretroviral activity, however this triple regimen i...

AI Technical Summary

Problems solved by technology

The currently recommended first-line treatment regimen for HIV-infected patients consists of protease inhibitors combined with two nucleoside reverse transcriptase inhibitors to produce high-potency antiretroviral activity, however this triple regimen is not effective in dual inhibition of viral replication. At the same time, related issues such as metabolism / resistance and drug-drug interactions have emerged

As a newly developed protease inhibitor, atazanavir has clear and unique drug resistance, strong curative effect and less side effects (reference: Chen Nana, a new type of HIV-1 protease inhibitor, foreign pharmaceutical antibiotics Fascicle [J], 2004, 25(4): 173-175); in order to further improve its bioavailability, it is used in combination with ritonavir in clinical practice to increase the plasma concentration and area under the drug-time curve of atazanavir However, in clinical application, it is found that the combination of drugs will also produce some adverse reactions, such as elevated blood lipids (references: ritonavir in anti-HIV drugs is more likely to cause elevated blood lipids, Chinese Information Herald [N], 2002, 17 (24 ):8)

Images